Literature DB >> 19546439

Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.

Kiyoyuki Ogata1, Matteo G Della Porta, Luca Malcovati, Cristina Picone, Norio Yokose, Akira Matsuda, Taishi Yamashita, Hideto Tamura, Junichi Tsukada, Kazuo Dan.   

Abstract

BACKGROUND: The diagnosis of myelodysplastic syndromes is not always straightforward when patients lack specific diagnostic markers, such as blast excess, karyotype abnormality, and ringed sideroblasts. DESIGN AND METHODS: We designed a flow cytometry protocol applicable in many laboratories and verified its diagnostic utility in patients without those diagnostic markers. The cardinal parameters, analyzable from one cell aliquot, were myeloblasts (%), B-cell progenitors (%), myeloblast CD45 expression, and channel number of side scatter where the maximum number of granulocytes occurs. The adjunctive parameters were CD11b, CD15, and CD56 expression (%) on myeloblasts. Marrow samples from 106 control patients with cytopenia and 134 low-grade myelodysplastic syndromes patients, including 81 lacking both ringed sideroblasts and cytogenetic aberrations, were prospectively analyzed in Japan and Italy.
RESULTS: Data outside the predetermined reference range in 2 or more parameters (multiple abnormalities) were common in myelodysplastic syndromes patients. In those lacking ringed sideroblasts and cytogenetic aberrations, multiple abnormalities were observed in 8/26 Japanese (30.8%) and 37/55 Italians (67.3%) when the cardinal parameters alone were considered, and in 17/26 Japanese (65.4%) and 42/47 Italians (89.4%) when all parameters were taken into account. Multiple abnormalities were rare in controls. When data from all parameters were used, the diagnostic sensitivities were 65% and 89%, specificities were 98% and 90%, and likelihood ratios were 28.1 and 8.5 for the Japanese and Italian cohorts, respectively.
CONCLUSIONS: This protocol can be used in the diagnostic work-up of low-grade myelodysplastic syndromes patients who lack specific diagnostic markers, although further improvement in diagnostic power is desirable.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546439      PMCID: PMC2719029          DOI: 10.3324/haematol.2009.008532

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

Review 1.  Myelodysplasia.

Authors:  M L Heaney; D W Golde
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

2.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors:  Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

3.  Academic calculations versus clinical judgments: practicing physicians' use of quantitative measures of test accuracy.

Authors:  M C Reid; D A Lane; A R Feinstein
Journal:  Am J Med       Date:  1998-04       Impact factor: 4.965

4.  Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.

Authors:  Sindhu Cherian; Jonni Moore; Andrew Bantly; Jo-Anne Vergilio; Peter Klein; Selina Luger; Adam Bagg
Journal:  Cytometry B Clin Cytom       Date:  2005-03       Impact factor: 3.058

5.  Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.

Authors:  M Stetler-Stevenson; D C Arthur; N Jabbour; X Y Xie; J Molldrem; A J Barrett; D Venzon; M E Rick
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  Refining clinical diagnosis with likelihood ratios.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2005 Apr 23-29       Impact factor: 79.321

Review 7.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

8.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.

Authors:  Denise A Wells; Martin Benesch; Michael R Loken; Carlos Vallejo; David Myerson; Wendy M Leisenring; H Joachim Deeg
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

9.  Flow cytometry in myelodysplastic syndromes: report from a working conference.

Authors:  Michael R Loken; Arjan van de Loosdrecht; Kiyoyuki Ogata; Alberto Orfao; Denise A Wells
Journal:  Leuk Res       Date:  2007-06-18       Impact factor: 3.156

Review 10.  Diagnostic flow cytometry for low-grade myelodysplastic syndromes.

Authors:  Kiyoyuki Ogata
Journal:  Hematol Oncol       Date:  2008-12       Impact factor: 5.271

View more
  29 in total

1.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Authors:  Matteo G Della Porta; Cristina Picone; Cristiana Pascutto; Luca Malcovati; Hideto Tamura; Hiroshi Handa; Magdalena Czader; Sylvie Freeman; Paresh Vyas; Anna Porwit; Leonie Saft; Theresia M Westers; Canan Alhan; Claudia Cali; Arjan A van de Loosdrecht; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

3.  Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

4.  Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.

Authors:  Uta Oelschlaegel; Theresia M Westers; Brigitte Mohr; Michael Kramer; Stefani Parmentier; Katja Sockel; Christian Thiede; Martin Bornhäuser; Gerhard Ehninger; Arjan A van de Loosdrecht; Uwe Platzbecker
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

5.  Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Valérie Bardet; Orianne Wagner-Ballon; Julien Guy; Céline Morvan; Camille Debord; Franck Trimoreau; Emmanuel Benayoun; Nicolas Chapuis; Nicolas Freynet; Cédric Rossi; Stéphanie Mathis; Marie-Pierre Gourin; Andréa Toma; Marie C Béné; Jean Feuillard; Estelle Guérin
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

6.  Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia.

Authors:  Matteo G Della Porta; Cristina Picone; Annamaria Tenore; Norio Yokose; Luca Malcovati; Mario Cazzola; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2014-01       Impact factor: 9.941

Review 7.  Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Authors:  Anna Porwit
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

8.  Utility of peripheral blood flow cytometry in differentiating low grade versus high grade myelodysplastic syndromes (MDS) and in the evaluation of cytopenias.

Authors:  Hooman H Rashidi; Xiangdong Xu; Huan-You Wang; Nelofar Q Shafi; Karuna Rameshkumar; Karen Messer; Brian R Smith; Michal G Rose
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

Review 9.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

10.  Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Authors:  Eline M P Cremers; Theresia M Westers; Canan Alhan; Claudia Cali; Heleen A Visser-Wisselaar; Dana A Chitu; Vincent H J van der Velden; Jeroen G Te Marvelde; Saskia K Klein; Petra Muus; Edo Vellenga; Georgina E de Greef; Marie-Cecile C J C Legdeur; Pierre W Wijermans; Marian J P L Stevens-Kroef; Pedro da Silva-Coelho; Joop H Jansen; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.